5OH2
Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Pyrrolidin-2-one (Butyrolactam)
Summary for 5OH2
Entry DOI | 10.2210/pdb5oh2/pdb |
Descriptor | Cereblon isoform 4, ZINC ION, pyrrolidin-2-one, ... (4 entities in total) |
Functional Keywords | teratogenicity, protein degradation, substrate recognition, ubiquitin ligase, unknown function |
Biological source | Magnetospirillum gryphiswaldense |
Total number of polymer chains | 3 |
Total formula weight | 41562.27 |
Authors | Boichenko, I.,Albrecht, R.,Lupas, A.N.,Hernandez Alvarez, B.,Hartmann, M.D. (deposition date: 2017-07-14, release date: 2018-10-10, Last modification date: 2024-01-17) |
Primary citation | Boichenko, I.,Bar, K.,Deiss, S.,Heim, C.,Albrecht, R.,Lupas, A.N.,Hernandez Alvarez, B.,Hartmann, M.D. Chemical Ligand Space of Cereblon. Acs Omega, 3:11163-11171, 2018 Cited by PubMed Abstract: The protein cereblon serves as a substrate receptor of a ubiquitin ligase complex that can be tuned toward different target proteins by cereblon-binding agents. This approach to targeted protein degradation is exploited in different clinical settings and has sparked the development of a growing number of thalidomide derivatives. Here, we probe the chemical space of cereblon binding beyond such derivatives and work out a simple set of chemical requirements, delineating the metaclass of cereblon effectors. We report co-crystal structures for a diverse set of compounds, including commonly used pharmaceuticals, but also find that already minimalistic cereblon-binding moieties might exert teratogenic effects in zebrafish. Our results may guide the design of a post-thalidomide generation of therapeutic cereblon effectors and provide a framework for the circumvention of unintended cereblon binding by negative design for future pharmaceuticals. PubMed: 31459225DOI: 10.1021/acsomega.8b00959 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.9 Å) |
Structure validation
Download full validation report